Project Grant HT94252410265
Award Date
5/1/24
Completion Date
4/30/26
Dollars Obligated
$420K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84103, USA
Similar Awards
The U.S. Department of Defense's Defense Health Agency awarded a $5,599,141.00 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Kuda Therapeutics, Inc., a woman-owned small business located in Salt Lake City, Utah. The grant, with a performance period from June 1, 2025, to May 31, 2028, supports the advancement of a novel, orally available ferroptosis inducer for the treatment of von Hippel-Lindau (VHL) disease. The project aims to further develop this...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $299,200.00 to support the development of a first-in-class small molecule treatment for epithelial ovarian cancer. The award, with a period of performance from June 1, 2025 to August 31, 2025, was granted to Microquin LTD, a biotechnology company focused on innovative medical solutions including gene therapies. The funding will advance Microquin's...
The Department of the Army Medical Command awarded Duke University a $472,184 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2024 to exploit ferropotosis for the treatment of RB1-deficient lethal prostate cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
This Project Grant from the Defense Health Agency provides $494,811 to the University of Cambridge under the Military Medical Research and Development program (CFDA 12.420) from April 1, 2023 to March 31, 2026. The grant funds research to elucidate and target clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
The Defense Health Agency awarded a $1,086,750.00 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the project "TARGETING ENVIRONMENTAL FERROPTOSIS PROTECTION AS NOVEL THERAPEUTIC STRATEGY FOR METASTATIC RENAL CELL CARCINOMA" and will be completed by Aug 31, 2026. The project aims to research novel therapeutic strategies for metastatic renal cell carcinoma by targeting environmental ferroptosis protection.